CA2485751A1 - Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions - Google Patents

Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions Download PDF

Info

Publication number
CA2485751A1
CA2485751A1 CA002485751A CA2485751A CA2485751A1 CA 2485751 A1 CA2485751 A1 CA 2485751A1 CA 002485751 A CA002485751 A CA 002485751A CA 2485751 A CA2485751 A CA 2485751A CA 2485751 A1 CA2485751 A1 CA 2485751A1
Authority
CA
Canada
Prior art keywords
methyl
denotes hydrogen
denotes
hydrogen
optionally
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002485751A
Other languages
English (en)
French (fr)
Inventor
Sophie Banzet
Hermann Duettmann
Annerose Mauz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2485751A1 publication Critical patent/CA2485751A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002485751A 2002-06-15 2003-06-04 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions Abandoned CA2485751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10226814.2 2002-06-15
DE10226814A DE10226814A1 (de) 2002-06-15 2002-06-15 Neue Arzneimittelkombinationen zur Behandlung ischämischer Zustände
PCT/EP2003/005813 WO2003105844A1 (de) 2002-06-15 2003-06-04 Arzneimittelkombinationen aus natriumkanalblockern und fibrinolytika zur behandlung ischämischer zustände

Publications (1)

Publication Number Publication Date
CA2485751A1 true CA2485751A1 (en) 2003-12-24

Family

ID=29719139

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002485751A Abandoned CA2485751A1 (en) 2002-06-15 2003-06-04 Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions

Country Status (6)

Country Link
EP (1) EP1515720A1 (de)
JP (1) JP2005536478A (de)
AU (1) AU2003250338A1 (de)
CA (1) CA2485751A1 (de)
DE (1) DE10226814A1 (de)
WO (1) WO2003105844A1 (de)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1941879A1 (de) * 2007-01-05 2008-07-09 PAION Deutschland GmbH Nervenschutzmittel zur Behandlung von neuronalen Schäden.

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19740110A1 (de) * 1997-09-12 1999-03-18 Boehringer Ingelheim Pharma Substituierte 1,2,3,4,5,6-Hexahydro-2,6-methano-3-benzazocin-10-ole, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP1471871B1 (de) * 2001-02-02 2007-05-02 Ortho-McNeil Pharmaceutical, Inc. Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin

Also Published As

Publication number Publication date
WO2003105844A1 (de) 2003-12-24
JP2005536478A (ja) 2005-12-02
EP1515720A1 (de) 2005-03-23
AU2003250338A1 (en) 2003-12-31
DE10226814A1 (de) 2004-01-08

Similar Documents

Publication Publication Date Title
EP1196190B1 (de) Verwendung von langkettigen n-alkyl derivaten von deoxynojirimycin mit glucocerebrosidase enzyme zur herstellung eines medikaments zur behandlung von mit glykolipiden akkumulation zusammenhängenden krankheiten
US7713928B1 (en) Ready-to-use bivalirudin compositions
JP2010526101A5 (de)
CA2629312C (en) Compositions and methods for treating cns disorders
WO2002030451A1 (en) Compositions and methods for reducing gnrh-induced bone loss
JP2021519764A (ja) 線維性疾患を処置する方法
US20030235576A1 (en) New drug combinations for the treatment of ischaemic conditions
US20030180282A1 (en) Method of treatment of thrombotic events
CA2485751A1 (en) Medicament combinations of sodium channel blockers and fibrinolytics for treating ischaemic conditions
US11364196B2 (en) Levothyroxine formulations for oral use
AU2010277725B2 (en) Otamixaban for treatment of elderly and renal impaired non-ST elevation myocardial infarction patients
JPS6391327A (ja) 有機化合物に関する改良
JP2006131628A (ja) オキシメタゾリン含有水性組成物
US20040087513A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
US20040057947A1 (en) Drug combinations based on magnesium salts and fibrinolytics
JP2007153820A (ja) フラビンアデニンジヌクレオチド含有水性組成物
US20050113391A1 (en) Anti-hypertensive composition and methods of treatment
Flanagan Tranexamic acid tamponade to control postoperative surgical hemorrhage
CA2491217A1 (en) New drug combinations based on sodium channel blockers and magnesium salts
CA2491712A1 (en) New drug combinations based on magnesium salts and fibrinolytics
JP2013500964A (ja) 静脈内イブプロフェンを用いた重篤な病気の患者の治療
NZ230742A (en) Thrombolytic composition comprising a plasminogen activator (tpa, uk or sk) and a thromboxane receptor antagonist; kits thereof; and process for preparation thereof
JPH02243634A (ja) 虚血後の心筋機能不全回復用医薬組成物
EP0431277A1 (de) Mischung eines Thromboxan-A2-Antagonisten mit einem thrombolytischen Mittel
EP3730137A1 (de) Therapeutikum für glaukom mit fp-agonist und blocker

Legal Events

Date Code Title Description
FZDE Dead